Hydroxychloroquine retinopathy

Eye (Basingstoke)

Volumn 31, Issue 6, 2017, Pages 828-845

  Yusuf, I H ^a   Sharma, S ^a   Luqmani, R ^b   Downes, S M ^a  

^a OXFORD EYE HOSPITAL   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHLOROQUINE; ERLOTINIB; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; VORINOSTAT; ANTIRHEUMATIC AGENT;

ASIAN; AUTOFLUORESCENCE IMAGING; BODY WEIGHT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG USE; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EYE TOXICITY; FUNDUS AUTOFLUORESCENCE; HEALTH CARE COST; HUMAN; IDEAL BODY WEIGHT; INCIDENCE; KIDNEY FAILURE; MALARIA; MALARIA FALCIPARUM; MULTIFOCAL ELECTRORETINOGRAPHY; NON SMALL CELL LUNG CANCER; ONCOLOGY; PERIMETRY; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREVALENCE; PROTOCOL COMPLIANCE; RETINA; RETINA MACULOPATHY; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT INDICATION; UNCERTAINTY; CHEMICALLY INDUCED; CONNECTIVE TISSUE DISEASE; DRUG EFFECTS; GLOBAL HEALTH; PATHOLOGY; RETINA DISEASE; VISUAL SYSTEM EXAMINATION;

ANTIRHEUMATIC AGENTS; CONNECTIVE TISSUE DISEASES; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; GLOBAL HEALTH; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; RETINA; RETINAL DISEASES; RISK FACTORS;

EID: 85020460756     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2016.298     Document Type: Review

References (106)

1. Gabourel JD. Effects of hydroxychloroquine on the growth of mammalian cells in vitro. J Pharmacol Exp Ther 1963; 141: 122-130.
2. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
3. Pons-Estel GJ, Alarcon GS, McGwin Jr G, Danila MI, Zhang J, Bastian HM et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61: 830-839.
4. Willis R, Seif AM, McGwin Jr G, Martinez-Martinez LA, Gonzalez EB, Dang N et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012; 21: 830-835.
5. Costedoat-Chalumeau N, Dunogue B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014; 43: e167-e180.
6. Jancinova V, Pazourekova S, Lucova M, Perecko T, Mihalova D, Bauerova K et al. Selective inhibition of extracellular oxidants liberated from human neutrophils-A new mechanism potentially involved in the antiinflammatory activity of hydroxychloroquine. Int Immunopharmacol 2015; 28: 175-181.
7. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95: 3460-3466.
8. van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol 2013; 131: 1443-6.e1.
9. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23: 82-91.
10. Scholl HP, Shah SM. We need to be better prepared for hydroxychloroquine retinopathy. JAMA Ophthalmol 2014; 132: 1460-1461.
11. BethelM, Yang FM, Li S, Nahman NS, Oliver AM,MachuaW et al. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. J Investig Med 2016; 64: 908-910.
12. Electronic Medicines Compendium. Plaquenil 200mg Filmcoated Tablets. 2014.
13. Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010; 8: 829-844 quiz 45.
14. Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol 2015; 50: 410-419.
15. Poklepovic A, Gewirtz DA. Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy 2014; 10: 1478-1480.
16. Cook KL, Warri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A et al. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res 2014; 20: 3222-3232.
17. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1602-1608.
18. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10: 1403-1414.
19. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1391-1402.
20. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A et al. Phase I trial of hydroxychloroquine with doseintense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1369-1379.
21. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10: 1380-1390.
22. The Royal College of Ophthalmologists. Hydroxychloroquine and Ocular ToxicityRecommendations on Screening, 2009.
23. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-1382.
24. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415-422.
25. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123: 1386-1394.
26. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23: 231-269.
27. Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon JB, Dallay D et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24: 1384-1391.
28. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-1460.
29. Giner Galvan V, Oltra MR, Rueda D, Esteban MJ, Redon J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 2007; 26: 971-972.
30. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994; 35: 569-570.
31. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13: 77-80.
32. Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR et al. Persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in U.S. veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2017; 69: 313-322.
33. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016; 353: i1777.
34. Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Mottonen T. Long-term results of the FIN-RACo trial; treatment with a combination of traditional diseasemodifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: S27-S31.
35. Xu C, Zhu L, Chan T, Lu X, Shen W, Madigan MC et al. Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci 2016; 105: 884-890.
36. Korthagen NM, Bastiaans J, van Meurs JC, van Bilsen K, van Hagen PM, Dik WA. Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. J Biochem Mol Toxicol 2015; 29: 299-304.
37. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978; 17: 1158-1175.
38. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012; 130: 461-469.
39. de Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 2015; 56: 3415-3426.
40. Bergholz R, Schroeter J, Ruther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol 2010; 94: 1637-1642.
41. Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol 2014; 8: 1401-1407.
42. Walvick MD, Walvick MP, Tongson E, Ngo CH. Hydroxychloroquine: lean body weight dosing. Ophthalmology 2011; 118: 2100.
43. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 775-784.
44. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993; 25: 385-388.
45. Cavagna L, Rossi P, Bogliolo L, Antoniazzi E, Gelmi C, Caporali R et al. [Early electroretinografic changes in elderly RA patients treated with hydroxychloroquine]. Reumatismo 2002; 54: 226-231.
46. Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 2176-2184.
47. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996; 14: 1018-1026.
48. Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, D'Amore PA. Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Invest Ophthalmol Vis Sci 2014; 55: 4747-4758.
49. Toimela T, Tahti H, Salminen L. Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res 1995; 27(Suppl 1): 150-153.
50. Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 2015; 160: 799-805.e1.
51. Navajas EV, Krema H, Hammoudi DS, Lipton JH, Simpson ER, Boyd S et al. Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol 2015; 50: 442-450.
52. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol 2004; 15: 503-507.
53. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 2001; 131: 761-766.
54. Grassmann F, Bergholz R, Mandl J, Jagle H, Ruether K, Weber BH. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol 2015; 15: 18.
55. Maugeri A, Flothmann K, Hemmrich N, Ingvast S, Jorge P, Paloma E et al. The ABCA4 2588G4C Stargardt mutation: single origin and increasing frequency from South-West to North-East Europe. Eur J Hum Genet 2002; 10: 197-203.
56. Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ et al. Early-onset stargardt disease: phenotypic and genotypic characteristics. Ophthalmology 2015; 122: 335-344.
57. Noupuu K, Lee W, Zernant J, Greenstein VC, Tsang S, Allikmets R. Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. Graefes Arch Clin Exp Ophthalmol 2015; 254: 865-872.
58. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110: 1321-1326.
59. Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 2014; 98: 200-206.
60. Brinkley Jr JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979; 88: 1-11.
61. Moschos MM, Nitoda E, Chatziralli IP, Gatzioufas Z, Koutsandrea C, Kitsos G. Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. Drug Des Devel Ther 2015; 9: 2993-2999.
62. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122: 110-116.
63. Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. Clin Ophthalmol 2015; 9: 943-952.
64. Browning DJ, Lee C. Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy. Clin Ophthalmol 2015; 9: 1499-1509.
65. Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, Srinivasan V, Wojtkowski M, Reichel E et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 2007; 125: 775-780.
66. de Sisternes L, Hu J, Rubin DL, Marmor MF. Analysis of inner and outer retinal thickness in patients using hydroxychloroquine prior to development of retinopathy. JAMA Ophthalmol; e-pub ahead of print 17 March 2016; doi:10.1001/jamaophthalmol.2016.0155.
67. Lee MG, Kim SJ, Ham DI, Kang SW, Kee C, Lee J et al. Macular retinal ganglion cell-inner plexiform layer thickness in patients on hydroxychloroquine therapy. Invest Ophthalmol Vis Sci 2014; 56: 396-402.
68. Turgut B, Turkcuoglu P, Serdar Koca S, Aydemir O. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 2009; 28: 607-609.
69. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 2006; 47: 3531-3538.
70. Gorovoy IR, Gorovoy MS. Fundus autofluorescence in hydroxychloroquine toxicity. JAMA Ophthalmol 2013; 131: 506.
71. Marmor MF. Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity. JAMA Ophthalmol 2013; 131: 1487-1488.
72. Cukras C, Huynh N, Vitale S, Wong WT, Ferris FL 3rd, Sieving PA. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology 2015; 122: 356-366.
73. Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG. Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 2015; 122: 1239-51.e4.
74. Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 2003; 48: 1764.
75. Marmor MF, Melles RB. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology 2014; 121: 1257-1262.
76. Browning DJ, Lee C. Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol 2014; 8: 1389-1399.
77. Au A, Parikh V, Modi YS, Ehlers JP, Schachat AP, Singh RP. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am J Ophthalmol 2015; 160: 561-8, e2.
78. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 2013; 131: 1187-1197.
79. Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 2014; 132: 1199-1208.
80. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 2015; 42: 2092-2097.
81. Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: A longitudinal cohort analysis. Arthritis Care Res (Hoboken) 2016; 68: 1295-1302.
82. Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013; 72: 1786-1792.
83. Jacob J, Paques M, Krivosic V, Dupas B, Couturier A, Kulcsar C et al. Meaning of visualizing retinal cone mosaic on adaptive optics images. Am J Ophthalmol 2015; 159: 118-23.e1.
84. Bae EJ, Kim KR, Tsang SH, Park SP, Chang S. Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive optics scanning laser ophthalmoscopy. Korean J Ophthalmol 2014; 28: 100-107.
85. Flores M, Debellemaniere G, Bully A, Meillat M, Tumahai P, Delbosc B et al. Reflectivity of the outer retina on spectraldomain optical coherence tomography as a predictor of photoreceptor cone density. Am J Ophthalmol 2015; 160: 588-95, e2.
86. Stepien KE, Han DP, Schell J, Godara P, Rha J, Carroll J. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc 2009; 107: 28-33.
87. Martinez-Costa L, Victoria Ibanez M, Murcia-Bello C, Epifanio I, Verdejo-Gimeno C, Beltran-Catalan E et al. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol 2013; 48: 400-405.
88. Molina-Martin A, Pinero DP, Perez-Cambrodi RJ. Decreased perifoveal sensitivity detected by microperimetry in patients using hydroxychloroquine and without visual field and fundoscopic anomalies. J Ophthalmol 2015; 2015: 437271.
89. Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF. Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. Eye (Lond) 2013; 27: 1044-1052.
90. Easterbrook M. RE. Microperimetry and the diagnosis of antimalarial maculopathy. Can J Ophthalmol 2014; 49: 307-308.
91. Latasiewicz M, Gourier G, Yusuf IH, Luqmani R, Sharma SM, Downes SM. Hydroxychloroquine retinopathy: an emerging problem. Eye (lond) 2017; 31: 972-976.
92. Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013; 40: 831-841.
93. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54: 3640-3647.
94. Fessler BJ, Alarcon GS, McGwin Jr G, Roseman J, Bastian HM, Friedman AW et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
95. Pons-Estel GJ, Alarcon GS, Gonzalez LA, Zhang J, Vila LM, Reveille JD et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) 2010; 62: 393-400.
96. Schmajuk G, Yazdany J, Trupin L, Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 386-392.
97. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 2012; 42: 968-978.
98. Kim HA, Choi HJ, Baek HJ, Lim MJ, Park W, Lee J et al. Nonsteroidal antiinflammatory drugs (NSAID) versus NSAID with hydroxychloroquine in treatment of chemotherapy-related arthropathy: open-label multicenter pilot study. J Rheumatol 2012; 39: 1902-1903.
99. Marchetti M, Baker MG, Noland MM. Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases. Dermatol Online J 2014; 20: 21250.
100. Albers SE, Glass LF, Fenske NA. Lichen planus subtropicus: direct immunofluorescence findings and therapeutic response to hydroxychloroquine. Int J Dermatol 1994; 33: 645-647.
101. Stoll DM. Treatment of cutaneous pseudolymphoma with hydroxychloroquine. J Am Acad Dermatol 1983; 8: 696-699.
102. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 2003; 9: 714-721.
103. Lagneaux L, Delforge A, Carlier S, Massy M, Bernier M, Bron D. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol 2001; 112: 344-352.
104. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 2002; 43: 1087-1095.
105. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10: 1359-1368.
106. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014; 19: 637-638.